PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30553002-0	2019	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.	quizartinib	125-136	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	16-20	
30553002-0	2019	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.	quizartinib	125-136	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	21-26	
30553002-3	2019	Quizartinib was transported by human ABCB1 in vitro, and by mouse (m)Abcb1 and mAbcg2 in vivo.	quizartinib	0-11	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	69-74	
30553002-4	2019	Upon oral administration, the brain accumulation of quizartinib was 6-fold decreased by mAbcb1 and 2-fold by mAbcg2 (together: 12-fold).	quizartinib	52-63	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	88-94	
30553002-5	2019	Unexpectedly, the absence of mAbcb1 resulted in a ~2-fold lower plasma exposure in Abcb1a/1b-/- and Abcb1a/1b;Abcg2-/- mice, suggesting that loss of mAbcb1 causes compensatory alterations in alternative quizartinib elimination or uptake systems.	quizartinib	203-214	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	29-35